Pharmalys Ltd

14/08/2026

Congratulations to the Wits Diagnostic Innovation Hub on the successful completion of its Good Clinical Laboratory Practice (GCLP) accreditation audit. Conducted by Pharmalys on 7–8 July 2026 across the laboratory's Parktown and Braamfontein sites in South Africa, the audit reflects Wits DIH's ongoing commitment to quality and excellence in clinical research.

Read the full article here

Discover how the Wits Diagnostic Innovation Hub successfully achieved Good Clinical Laboratory Practice (GCLP) accreditation with Pharmalys, reinforcing quality systems, data integrity, and excellence in clinical research across its Parktown and Braamfontein laboratories in South Africa.

10/08/2026

New research has identified immune that may help predict which patients are at risk of developing chronic critical illness in the intensive care unit (ICU). Early identification could enable faster intervention, improve patient outcomes, and reduce prolonged stays. This highlights the growing role of , , and in advancing critical care.

New research, published in The Journal of Immunology, identified biomarkers of a distinct immune profile that could be used to identify patients at risk for chronic critical illness (CCI) upon admittance to the intensive-care unit (ICU) after traumatic injury.

08/08/2026

In Zambia, where cancer is the leading cancer killer and access to specialists is limited, nurses are driving the response through expanded screening, treatment, and vaccination. This nurse-led model is improving early detection and access to care, showing the importance of strong primary healthcare systems in the fight against cancer in low-resource settings. Strengthening , , and nurse-led care is key to improving women’s health outcomes.

It has the third-highest rate of cervical cancer in the world, and just a handful of oncologists. But that’s not stopping Zambia from bringing the fight to cervical cancer.

07/08/2026

We're proud to share highlights from Pharmalys' participation in the CEPI Collaboration Networking Meeting in Cape Town, where global partners came together to advance epidemic preparedness and strengthen clinical research capacity. As an invited speaker, our Laboratory Solutions and GCLP Team Lead, Jeanette, shared insights on building quality systems that support resilient, globally harmonised clinical research.

Read more about the event here https://www.pharmalys.com/pharmalys-at-the-cepi-collaboration-networking-meeting-cape-town-june-2026/

Coalition for Epidemic Preparedness Innovations - CEPI

Pharmalys joined the CEPI Collaboration Networking Meeting in Cape Town, highlighting GCLP accreditation, laboratory quality and global clinical research excellence.

05/08/2026

Around 655 million people still live without electricity, while 2 billion rely on polluting fuels for cooking, with serious consequences for health and well-being. Expanding access to clean, affordable energy and accelerating the transition to renewables are essential to improve lives, reduce inequalities, and achieve the Sustainable Development Goal 7 (SDG7), which aims to ensure access to affordable, reliable, sustainable, and modern energy for all. Stronger action on , , and is urgently needed to close the global access gap.

Latest data show uneven progress, highlighting the critical need to focus on affordability and vulnerable communities

03/08/2026

is calling on countries to strengthen screening to detect birth defects early and ensure timely diagnosis and treatment. Early detection can save lives, prevent lifelong disabilities, and give every child the best start in life. Expanding access to screening and integrating it into routine health services is essential to improving child survival, especially in low- and middle-income countries.

The World Health Organization (WHO) today calls on countries to expand newborn screening for birth defects, highlighting how early detection and treatment can save lives and reduce lifelong disability for millions of children.A new WHO report, Strengthening capacity for newborn screening, diagnosis....

31/07/2026

Congratulations to our partnerCoalition for Epidemic Preparedness Innovations - CEPI on the launch of the CEPI 3.0 Investment Case and Strategy.

CEPI 3.0 will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Through focused investments in three interconnected priority areas, CEPI will advance vaccines for both known and emerging viral threats, strengthen platform technologies so they are ready and available to accelerate vaccine development and support global networks that are ready to respond to future threats swiftly and equitably, whenever and wherever they emerge.

To deliver this, CEPI is now seeking US$2.5 billion in new funding to unlock the plan’s transformational potential and secure a safer, better prepared future for all.

Learn more: https://cepi.net/securing-the-future



Read the full article here https://www.pharmalys.com/cepi-3-pandemic-preparedness-pharmalys/

Discover how Pharmalys supports CEPI 3.0 and the 100 Days Mission to strengthen global pandemic preparedness through faster vaccine development and research collaboration.

29/07/2026

The global rush for critical minerals such as lithium and cobalt is powering the clean energy and digital transition, but a new report warns it is also deepening environmental degradation, water insecurity, and health risks in vulnerable mining regions, particularly in the DRC and South America’s Lithium Triangle, raising urgent concerns about sustainable development and equitable resource governance.

Mining of minerals such as lithium and cobalt risks eroding water security in DRC and parts of Latin America, UN report warns.

28/07/2026

Some wonderful feedback for Mbaye, Clinical Project Manager and Clinical Operations Team Lead at Pharmalys. A huge thank you to UCL Innovative Clinical Trials Unit for taking the time to share these kind words, and congratulations to Mbaye on this well deserved recognition.

You can read more client testimonials on our website homepage (if you scroll to the bottom!) https://www.pharmalys.com/

27/07/2026

Breakthroughs in cancer research are accelerating as TIL therapies, personalised treatments using a patient’s own tumor-infiltrating immune cells, move from decades of experimental science to real-world clinical impact, offering new hope for hard-to-treat solid tumors and reshaping the future of immunotherapy.

Two years after the first FDA approval of TIL therapy, how has the field evolved, and what comes next for treating solid tumors?